首页> 外文期刊>The Journal of Endocrinology: The Journal of the Society for Endocrinology >Long-term oral exposure to bisphenol A induces glucose intolerance and insulin resistance
【24h】

Long-term oral exposure to bisphenol A induces glucose intolerance and insulin resistance

机译:长期口服双酚A会引起葡萄糖耐量下降和胰岛素抵抗

获取原文
           

摘要

Bisphenol A (BPA) is a widely used endocrine disruptor. Recent epidemiologic results have suggested an association between exposure to BPA and cardiovascular disease, type 2 diabetes, and obesity. We investigated the in vivo effects of long-term oral exposure to BPA on insulin resistance and glucose intolerance. In the present study, 4- to 6-week-old male mice on a high-fat diet (HFD) were treated with 50?μg/kg body weight per day of BPA orally for 12 weeks. Long-term oral exposure to BPA along with an HFD for 12 weeks induced glucose intolerance in growing male mice. Intraperitoneal glucose tolerance tests showed that the mice that received an HFD and BPA exhibited a significantly larger area under the curve than did those that received an HFD only (119.9±16.8 vs 97.9±18.2?mM/min, P =0.027). Body weight, percentage of white adipose tissue, and percentage of body fat did not differ between the two groups of mice. However, treatment with BPA reduced Akt phosphorylation at position Thr308 and GSK3β phosphorylation at position Ser9 in skeletal muscle. BPA tended to decrease serum adiponectin levels and to increase serum interleukin 6 and tumor necrosis factor α, although these findings were not statistically significant. Treatment with BPA did not induce any detrimental changes in the islet area or morphology or the insulin content of β cells. In conclusion, long-term oral exposure to BPA induced glucose intolerance and insulin resistance in growing mice. Decreased Akt phosphorylation in skeletal muscle by way of altered serum adipocytokine levels might be one mechanism by which BPA induces glucose intolerance.
机译:双酚A(BPA)是一种广泛使用的内分泌干扰物。最近的流行病学结果表明,接触BPA与心血管疾病,2型糖尿病和肥胖之间存在关联。我们调查了长期口服BPA对胰岛素抵抗和葡萄糖耐受不良的体内影响。在本研究中,对高脂饮食(HFD)的4至6周龄的雄性小鼠每天口服BPA 50?μg/ kg体重治疗12周。长期口服BPA以及HFD持续12周会诱发成年雄性小鼠的葡萄糖耐受不良。腹膜内葡萄糖耐量测试显示,接受HFD和BPA的小鼠的曲线下面积比仅接受HFD的小鼠大得多(119.9±16.8 vs 97.9±18.2?mM / min,P = 0.027)。两组小鼠的体重,白色脂肪组织的百分比和体脂的百分比没有差异。但是,用BPA进行治疗可减少骨骼肌中Thr308位的Akt磷酸化和Ser9位的GSK3β磷酸化。 BPA倾向于降低血清脂联素水平并增加血清白介素6和肿瘤坏死因子α,尽管这些发现在统计学上并不显着。用BPA治疗不会引起胰岛面积或形态或β细胞胰岛素含量的任何有害变化。总之,长期口服BPA会诱导生长中的小鼠出现葡萄糖耐受不良和胰岛素抵抗。通过改变血清脂肪细胞因子水平而降低骨骼肌中Akt磷酸化可能是BPA诱导葡萄糖耐受不良的一种机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号